Obicetrapib
Obicetrapib tied to sizable LDL lowering on top of other therapies in high-risk patients
CHICAGO — In patients with heterozygous familial hypercholesterolemia with high LDL despite being on optimal medical therapy, obicetrapib greatly lowered LDL levels compared with placebo, according to the results of the BROOKLYN trial.
Top-line data show durable LDL lowering with obicetrapib for adults with HeFH
Obicetrapib significantly reduced LDL vs. placebo in adults with heterozygous familial hypercholesterolemia and uncontrolled LDL, despite maximally tolerated therapy, according to the top-line results of the phase 3 BROOKLYN clinical trial.
Obicetrapib, alone or with ezetimibe, reduces atherogenic lipoprotein particles
ATLANTA — Obicetrapib, a novel cholesteryl ester transfer protein inhibitor, reduced atherogenic lipoprotein particles alone or in combination with ezetimibe, according to new data from the ROSE2 trial.
ROSE2: Obicetrapib/ezetimibe combination further lowers LDL in statin-treated patients
In statin-treated patients with dyslipidemia, the combination of obicetrapib and ezetimibe further lowered LDL, according to the results of the phase 2 ROSE2 trial.
Pipeline Pulse: A look at tirzepatide, ziltivekimab and obicetrapib
The field of cardiology has seen stunning advances in the past several years: HF, dyslipidemia and cardiomyopathy are just three of the disorders in which there have been recent practice-changing therapeutic innovations.